8-K: Azenta Reports Strong Start to Fiscal 2025 with 4% Revenue Growth

Azenta, Inc. announced its first quarter fiscal 2025 results, showcasing a 4% year-over-year revenue increase and positive momentum in Sample Management Solutions and Multiomics services.

Summary

• Azenta, Inc. reported its financial results for the first quarter of fiscal year 2025, which ended on December 31, 2024.
• Revenue from continuing operations was $148 million, a 4% increase compared to the same quarter last year.
• Organic revenue also grew by 4% year-over-year.
• Sample Management Solutions revenue reached $81 million, up 3% year-over-year, driven by growth in Sample Repository Solutions and Core Products.
• Multiomics revenue increased to $66 million, a 6% rise year-over-year, primarily due to growth in Next Generation Sequencing and Gene Synthesis.
• The company's operating loss was $11 million, but the operating margin improved by 380 basis points year-over-year to (7.7)%.
• Adjusted EBITDA was $13 million, with an Adjusted EBITDA margin of 9.0%, reflecting an improvement of 400 basis points year-over-year.
• Diluted EPS from continuing operations was ($0.21), compared to ($0.13) in the first quarter of fiscal year 2024.
• The company ended the quarter with $530 million in cash, cash equivalents, restricted cash, and marketable securities.
• Operating cash flow was $30 million, and free cash flow was $22 million.
• Azenta is reiterating its full-year fiscal 2025 guidance, expecting organic revenue growth in the range of 3% to 5% and Adjusted EBITDA margin expansion of approximately 300 basis points relative to fiscal 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company reported a loss, there are several positive indicators, including revenue growth, improved EBITDA margin, and a strong cash position. The reiteration of full-year guidance also suggests confidence in future performance.

Positives

• Revenue increased by 4% year-over-year, indicating growth in the company's core business.
• Organic revenue growth of 4% suggests that the company's growth is not solely reliant on external factors.
• The Adjusted EBITDA margin improved by 400 basis points year-over-year, demonstrating improved profitability.
• The company has a strong cash position with $530 million in cash, cash equivalents, restricted cash, and marketable securities.
• Free cash flow was positive at $22 million, indicating the company's ability to generate cash.
• Gross margin was 46.6%, up 300 basis points year over year, driven by higher revenue, favorable sales mix, operational efficiencies, lower amortization costs, and certain non-recurring items recorded in the same period last year.

Negatives

• The company reported an operating loss of $11 million.
• Diluted EPS from continuing operations was ($0.21), which is a loss.
• Diluted EPS from discontinued operations was ($0.09).
• Total diluted EPS was ($0.29), compared to ($0.28) a year ago.

Risks

• The company's ability to reduce costs effectively could impact future profitability.
• Volatility in the life sciences markets could affect demand for the company's products and services.
• Difficulties in obtaining components and materials from suppliers could impact the company's ability to meet demand.
• Customers' inability to make payments could negatively impact the company's financial performance.
• Disputes concerning intellectual property could lead to legal costs and impact the company's competitive position.
• Uncertainties in global political and economic conditions could affect the company's operations and financial results.

Future Outlook

The company is reiterating its revenue guidance for fiscal year 2025, expecting total organic revenue to grow in the range of 3% to 5% relative to fiscal 2024 and Adjusted EBITDA margin expansion of approximately 300 basis points relative to fiscal 2024.

Management Comments

• 'Our first quarter results represent a strong start to fiscal 2025 as we see positive momentum in the demand for our unique offering of Sample Management Solutions and Multiomics services,' stated John Marotta, President and CEO.
• Management believes that starting the year like this gives them confidence in the strength of their unique market positioning, value proposition and ability to continue evolving to their customers' needs while delivering profitable growth.
• Management is encouraged by the progress they are making and the strong free cash flow.

Industry Context

Azenta operates in the life sciences industry, providing sample management solutions and multiomics services. The company's performance is influenced by trends in drug development, clinical research, and advanced cell therapies. The growth in Multiomics revenue aligns with the increasing demand for next-generation sequencing and gene synthesis services.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing Azenta's specific competitors and their Q1 2025 results.
• However, companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies also operate in the life sciences tools and services market.
• Comparing Azenta's 4% revenue growth and 9% Adjusted EBITDA margin to these larger players' performance would provide a better understanding of its relative performance.
• For example, if Thermo Fisher Scientific reported 6% revenue growth and a 25% operating margin, it would suggest that Azenta is growing slower and is less profitable.
• Similarly, comparing Azenta's Sample Management Solutions and Multiomics growth rates to those of specialized competitors in these segments would be insightful.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and improved profitability, but concerned about the reported loss.
• Employees may be positively impacted by the company's growth and strong financial position.
• Customers should benefit from the company's continued investment in its products and services.
• Suppliers may see increased demand for their products and services as the company grows.
• Creditors may view the company's strong cash position favorably.

Next Steps

• Azenta management will host a conference call and webcast to discuss the first quarter fiscal 2025 earnings.
• Management will respond to questions concerning the company's financial performance, business conditions, and industry outlook.

Key Dates

Keywords

Azenta, financial results, revenue, EBITDA, Sample Management Solutions, Multiomics, organic growth, earnings, life sciences